Inactive

Takeda Seeks Startups working on 4 therapeutic areas

Deadline: March 4, 2022

Takeda is looking for new approaches and technologies that can help them address key business challenges/opportunities in 4 major therapeutic areas. Interests include but not limited to:

AREA 1: Gastroenterology

Disease Areas

•Inflammatory Bowel Disease

•Celiac Disease

•Liver Disease

•Motility disorders

Interests

•Targeted-delivery technologies

•Novel anti-fibrotic approaches for liver and fibrostenotic diseases

•Approaches to study and modulate neuroinflammation in the GI tract

AREA 2: Oncology

Disease Areas

•Hematologic Malignancies; Solid tumors

Interests

•Novel innate immune cell targets, next gen innate cell engagers, therapies, platforms

•Allogeneic cell therapies and enabling technology

•Novel targets related to genomic instability /mutation

AREA 3: Neuroscience

Disease Areas

•Neurodegeneration

•Huntington's Disease

•Hereditary ataxias (FA)

•Neuromuscular

•Hypersommia, epilepsy

Interests

•Novel small molecule RNA modulation and protein degrader platforms

•Enhanced delivery technology

•Biomarkers, imaging tools

AREA 4: Rare Genetic & Hematology

Disease Areas

•Lysosomal storage disorders

•Rare non-malignant hematologic diseases

•Rare Renal disorders

Interests

•Next-generation gene therapy/gene editing technologies

•Non-viral gene therapy delivery technologies that allow re-dosing

•Gene therapy enhancements

PROCESS OVERVIEW

- All responses will be reviewed and you will be notified as to whether the response has been accepted for further consideration.

- If accepted, you will be contacted to present additional detail on your company and solution.

Deadline: March 4, 2022

February 10, 2022

Takeda is looking for new approaches and technologies that can help them address key business challenges/opportunities in 4 major therapeutic areas. Interests include but not limited to:

AREA 1: Gastroenterology

Disease Areas

•Inflammatory Bowel Disease

•Celiac Disease

•Liver Disease

•Motility disorders

Interests

•Targeted-delivery technologies

•Novel anti-fibrotic approaches for liver and fibrostenotic diseases

•Approaches to study and modulate neuroinflammation in the GI tract

AREA 2: Oncology

Disease Areas

•Hematologic Malignancies; Solid tumors

Interests

•Novel innate immune cell targets, next gen innate cell engagers, therapies, platforms

•Allogeneic cell therapies and enabling technology

•Novel targets related to genomic instability /mutation

AREA 3: Neuroscience

Disease Areas

•Neurodegeneration

•Huntington's Disease

•Hereditary ataxias (FA)

•Neuromuscular

•Hypersommia, epilepsy

Interests

•Novel small molecule RNA modulation and protein degrader platforms

•Enhanced delivery technology

•Biomarkers, imaging tools

AREA 4: Rare Genetic & Hematology

Disease Areas

•Lysosomal storage disorders

•Rare non-malignant hematologic diseases

•Rare Renal disorders

Interests

•Next-generation gene therapy/gene editing technologies

•Non-viral gene therapy delivery technologies that allow re-dosing

•Gene therapy enhancements

PROCESS OVERVIEW

- All responses will be reviewed and you will be notified as to whether the response has been accepted for further consideration.

- If accepted, you will be contacted to present additional detail on your company and solution.

To apply, please provide a slide deck with:

Concise description of your technology and match with Takeda request.
Concise description of current market traction (e.g. validations, proof of concept, partnerships, etc) and description of 1 compelling case.

To apply, please provide a slide deck with:
Concise description of your technology and match with Takeda request.

Concise description of current market traction (e.g. validations, proof of concept, partnerships, etc) and description of 1 compelling case.

Disclaimer: MIT Startup Exchange can make introductions that ideally provide open ended discussions in order to share mutual interests and potentially create common ground that incite the parties to collaborate. MIT Startup Exchange introductions may eventually lead to mutual partnerships, but that is not in any way guaranteed by MIT, MIT Corporate Relations, MIT Industrial Liaison Program (ILP) or MIT Startup Exchange, which takes no responsibility for these outcomes and no formal part in such discussions following our introduction. MIT Startup Exchange and its activities and events are not for purposes of soliciting investment or offering securities.